Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Botanix Pharmaceuticals Limited ( (AU:BOT) ).
Botanix Pharmaceuticals has formalized a securities trading policy that applies to its directors, officers, employees, consultants and contractors globally, setting clear rules for dealing in company securities. The policy aims to uphold high standards of corporate conduct, protect the company’s reputation and support market confidence in trading its shares by ensuring all personnel understand their obligations.
The policy summarizes Australian insider trading laws, clarifies what constitutes inside information, and emphasizes that legal prohibitions override any internal approvals or trading windows. By tightening governance around securities dealing and reinforcing compliance with the Corporations Act and ASX requirements, Botanix seeks to reduce misconduct risk and enhance transparency for investors and other stakeholders.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$0.14 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a pharmaceutical company focused on developing and commercializing therapeutics, operating within the regulated framework of the Australian securities market. The company is listed on the ASX and must comply with Australian corporate and securities laws governing trading in its securities.
Average Trading Volume: 23,992,151
Technical Sentiment Signal: Sell
Current Market Cap: A$68.01M
Learn more about BOT stock on TipRanks’ Stock Analysis page.